Keystone Labs Court-Ordered To Halt OTC Drug Manufacturing; Cosmetics Not Affected, It Says
This article was originally published in The Rose Sheet
Executive Summary
Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.